JP2019514907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514907A5 JP2019514907A5 JP2018556273A JP2018556273A JP2019514907A5 JP 2019514907 A5 JP2019514907 A5 JP 2019514907A5 JP 2018556273 A JP2018556273 A JP 2018556273A JP 2018556273 A JP2018556273 A JP 2018556273A JP 2019514907 A5 JP2019514907 A5 JP 2019514907A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- statin
- angptl3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 claims 18
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 17
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 15
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 claims 13
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 10
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 9
- 239000003524 antilipemic agent Substances 0.000 claims 8
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 7
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 7
- 229960003566 lomitapide Drugs 0.000 claims 7
- 230000001906 cholesterol absorption Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940047695 juxtapid Drugs 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 229960000815 ezetimibe Drugs 0.000 claims 5
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 4
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 claims 4
- 229940066901 crestor Drugs 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 229940002661 lipitor Drugs 0.000 claims 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 4
- 229960000672 rosuvastatin Drugs 0.000 claims 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 4
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 4
- 229940051223 zetia Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 3
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 229940095570 lescol Drugs 0.000 claims 2
- 229940092923 livalo Drugs 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940099246 mevacor Drugs 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960002797 pitavastatin Drugs 0.000 claims 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 229940072168 zocor Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940089484 pravachol Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022145714A JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328823P | 2016-04-28 | 2016-04-28 | |
| US62/328,823 | 2016-04-28 | ||
| US201662348001P | 2016-06-09 | 2016-06-09 | |
| US62/348,001 | 2016-06-09 | ||
| US201762451310P | 2017-01-27 | 2017-01-27 | |
| US62/451,310 | 2017-01-27 | ||
| PCT/US2017/029782 WO2017189813A1 (en) | 2016-04-28 | 2017-04-27 | Methods for treating patients with familial hypercholesterolemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145714A Division JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514907A JP2019514907A (ja) | 2019-06-06 |
| JP2019514907A5 true JP2019514907A5 (enExample) | 2020-05-28 |
| JP7201437B2 JP7201437B2 (ja) | 2023-01-10 |
Family
ID=58692626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556273A Active JP7201437B2 (ja) | 2016-04-28 | 2017-04-27 | 家族性高コレステロール血症を有する患者を処置するための方法 |
| JP2022145714A Active JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145714A Active JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20170312359A1 (enExample) |
| EP (1) | EP3448426B1 (enExample) |
| JP (2) | JP7201437B2 (enExample) |
| KR (3) | KR20240019856A (enExample) |
| CN (1) | CN109069641A (enExample) |
| AU (1) | AU2017258105B2 (enExample) |
| CA (1) | CA3021884A1 (enExample) |
| DK (1) | DK3448426T3 (enExample) |
| ES (1) | ES3032667T3 (enExample) |
| FI (1) | FI3448426T3 (enExample) |
| HR (1) | HRP20250797T1 (enExample) |
| HU (1) | HUE071912T2 (enExample) |
| IL (2) | IL262591B (enExample) |
| LT (1) | LT3448426T (enExample) |
| MA (1) | MA44764B1 (enExample) |
| MD (1) | MD3448426T2 (enExample) |
| MX (1) | MX2018012741A (enExample) |
| PL (1) | PL3448426T3 (enExample) |
| PT (1) | PT3448426T (enExample) |
| RS (1) | RS66975B1 (enExample) |
| SI (1) | SI3448426T1 (enExample) |
| SM (1) | SMT202500230T1 (enExample) |
| WO (1) | WO2017189813A1 (enExample) |
| ZA (1) | ZA201806557B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| EA201891979A1 (ru) | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| WO2019105437A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105418A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| KR102617947B1 (ko) | 2017-12-29 | 2023-12-27 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 접합체와 제조 및 그 용도 |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| WO2020063198A1 (zh) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| WO2020135581A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| JP7692411B2 (ja) * | 2019-11-07 | 2025-06-13 | メディミューン，エルエルシー | 心血管疾患の治療用の内皮リパーゼ抗体 |
| WO2021154079A1 (en) | 2020-01-29 | 2021-08-05 | Rijksuniversiteit Groningen | Means and methods for modulating lipid metabolism |
| JP2023536855A (ja) * | 2020-07-29 | 2023-08-30 | アムリット・ファーマシューティカルズ・インコーポレイテッド | 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド |
| WO2022032137A1 (en) * | 2020-08-07 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
| CN116948030B (zh) * | 2022-04-25 | 2024-11-19 | 武汉大学 | 抗asgr1单克隆抗体及其应用 |
| EP4518969A1 (en) | 2022-05-02 | 2025-03-12 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| CN119192369A (zh) * | 2023-06-25 | 2024-12-27 | 百奥泰生物制药股份有限公司 | 抗angptl3抗体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US730654A (en) * | 1902-04-17 | 1903-06-09 | John W Hornsey | Hot-air furnace. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1273112C (zh) * | 2001-02-22 | 2006-09-06 | 斯凯伊药品加拿大公司 | 具有减少进食－禁食作用的贝特－它汀组合 |
| ES2618830T3 (es) * | 2006-12-08 | 2017-06-22 | Lexicon Pharmaceuticals, Inc. | Anticuerpos monoclonales contra ANGPTL3 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| EP2216016A1 (en) * | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| US8653047B2 (en) * | 2010-01-08 | 2014-02-18 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| CA2930069A1 (en) | 2013-11-20 | 2015-05-28 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| CN111440795A (zh) * | 2013-12-24 | 2020-07-24 | Ionis制药公司 | 促血管生成素样3表达的调节 |
| KR102356388B1 (ko) * | 2014-05-01 | 2022-01-26 | 아이오니스 파마수티컬즈, 인코포레이티드 | 안지오포이에틴-유사 3 발현을 조절하기 위한 조성물 및 방법 |
| EA201891979A1 (ru) * | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| PL3439689T3 (pl) * | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
-
2017
- 2017-04-27 HU HUE17722604A patent/HUE071912T2/hu unknown
- 2017-04-27 RS RS20250643A patent/RS66975B1/sr unknown
- 2017-04-27 IL IL262591A patent/IL262591B/en unknown
- 2017-04-27 SI SI201731609T patent/SI3448426T1/sl unknown
- 2017-04-27 DK DK17722604.0T patent/DK3448426T3/da active
- 2017-04-27 PT PT177226040T patent/PT3448426T/pt unknown
- 2017-04-27 HR HRP20250797TT patent/HRP20250797T1/hr unknown
- 2017-04-27 KR KR1020247003356A patent/KR20240019856A/ko active Pending
- 2017-04-27 LT LTEPPCT/US2017/029782T patent/LT3448426T/lt unknown
- 2017-04-27 CN CN201780026147.XA patent/CN109069641A/zh active Pending
- 2017-04-27 ES ES17722604T patent/ES3032667T3/es active Active
- 2017-04-27 MA MA44764A patent/MA44764B1/fr unknown
- 2017-04-27 PL PL17722604.0T patent/PL3448426T3/pl unknown
- 2017-04-27 MD MDE20190270T patent/MD3448426T2/ro unknown
- 2017-04-27 CA CA3021884A patent/CA3021884A1/en active Pending
- 2017-04-27 AU AU2017258105A patent/AU2017258105B2/en active Active
- 2017-04-27 SM SM20250230T patent/SMT202500230T1/it unknown
- 2017-04-27 US US15/498,687 patent/US20170312359A1/en not_active Abandoned
- 2017-04-27 FI FIEP17722604.0T patent/FI3448426T3/fi active
- 2017-04-27 EP EP17722604.0A patent/EP3448426B1/en active Active
- 2017-04-27 IL IL293308A patent/IL293308B2/en unknown
- 2017-04-27 KR KR1020187034616A patent/KR20190003679A/ko not_active Ceased
- 2017-04-27 KR KR1020227036013A patent/KR20220148299A/ko not_active Ceased
- 2017-04-27 MX MX2018012741A patent/MX2018012741A/es unknown
- 2017-04-27 JP JP2018556273A patent/JP7201437B2/ja active Active
- 2017-04-27 WO PCT/US2017/029782 patent/WO2017189813A1/en not_active Ceased
-
2018
- 2018-10-03 ZA ZA2018/06557A patent/ZA201806557B/en unknown
-
2019
- 2019-11-07 US US16/677,319 patent/US20200061189A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/859,996 patent/US20230000976A1/en not_active Abandoned
- 2022-09-14 JP JP2022145714A patent/JP7404471B2/ja active Active
-
2025
- 2025-07-14 US US19/268,651 patent/US20250332254A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514907A5 (enExample) | ||
| JP2022177142A5 (enExample) | ||
| JP7404471B2 (ja) | 家族性高コレステロール血症を有する患者を処置するための方法 | |
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2014516953A5 (enExample) | ||
| CN103732624B (zh) | 抗angptl3抗体及其用途 | |
| JP2017528427A5 (enExample) | ||
| JP2013023499A5 (enExample) | ||
| HRP20200545T1 (hr) | Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom | |
| JP2017506626A5 (enExample) | ||
| JP2016538248A5 (enExample) | ||
| JP2016520616A5 (enExample) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2016538277A5 (enExample) | ||
| JP2015530867A5 (enExample) | ||
| US12281173B2 (en) | Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor | |
| JP2019512472A5 (enExample) | ||
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2016523847A5 (enExample) | ||
| JP2019513751A5 (enExample) | ||
| JP2017522316A5 (enExample) | ||
| JP2022000443A5 (enExample) | ||
| RU2015101113A (ru) | Антитела против pcsk9, составы, дозы и способы применения | |
| RU2013156848A (ru) | Лечение антителами против pcsk9 | |
| JP2018138551A (ja) | 関節リウマチの治療 |